AURA · Aura Biosciences, Inc.
$7.02
-0.03 (-0.43%)
At close · Jul 29
Going-concern doubt
— cleared May 11, 2026
The latest filing states the doubt was alleviated.
“As disclosed in the Company's audited consolidated financial statements as of and for the year ended December 31, 2025, events and conditions existed which raised substantial doubt about the Company's ability to continue as a going concern, primarily due to recurring operating losses, negative cash flows from operations and liquidity constraints. Subsequent to year end, the Company completed the 2026 Follow-On Offering, raising approximately $241.8 million in net proceeds after completion of the Matrix Repurchase. Based on the successful execution of this financing, management has concluded that the events and conditions that previously raised substantial doubt have been alleviated.”View the 10-Q filed May 11, 2026
Market Cap
$724.74M
Shares
103.39M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Elisabet de los Pinos | CEO | $6,816,256 |
| Cadmus C. Rich | Chief Medical Officer | $2,398,624 |
| Julie B. Feder | CFO | $2,339,855 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Elisabet de los Pinos | CEO | $1,094,900 |
| Cadmus C. Rich | Chief Medical Officer | $632,366 |
| Julie B. Feder | CFO | $552,342 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jeremy Bender, Ph.D., M.B.A. | Class II director | Appointed | 2026-07-08 |
| Natalie Holles | Class I director with a term expiring at the Company's 2028 annual meeting of stockholders | Appointed | 2026-05-04 |
| Natalie Holles | Chief Executive Officer and President | Appointed | 2026-05-04 |
Key facts
CIK
1501796
CUSIP
05153U107
13F (30d)
18 filings
18 filers
Visit website
Investor relations